Boehringer Ingelheim Animal Health
|Revenue||€4 billion (2019)|
Number of employees
Boehringer Ingelheim Animal Health is a multinational animal health company, formed in January 2017 when Merial was acquired by Boehringer Ingelheim and merged with Boehringer Ingelheim's existing animal health assets.
In August 1997, Merial started as a joint venture between the animal health subsidiaries of Merck & Co. (MSD AgVet) and Sanofi-Aventis (Rhône-Mérieux). Merial became the animal health division of Sanofi, when Sanofi bought out Merck's 50% share of the joint venture. On December 30, 2016 Boehringer Ingelheim completed a swap of their OTC business for Sanofi's animal health business. Merial is now owned by Boehringer Ingelheim and combined with their animal health business, Boehringer Ingelheim Vetmedica, to form Boehringer Ingelheim Animal Health.
Merial produces many products and vaccines for domestic pets, farm animals and wildlife. Merial has about 6,900 employees and is present in more than 150 countries in the world. Their sales in 2015 were about €2.5 billion. Some of Merial's most popular products are Frontline, Heartgard, NexGard, Ivomec, PureVax and Previcox.
In October 2009, Merial announced it was investing 70 million US$ at its poultry vaccines plant in Nanchang Hi-tech Development Zone, China. On March 9, 2010, Sanofi-Aventis announced it had exercised an option to combine Merial with Intervet/Schering Plough, the animal health business of Merck. The new joint venture would be equally owned by Merck and Sanofi-Aventis. On March 22, 2011, they announced the mutual termination of their agreement to form a new animal health joint venture.
Boehringer Ingelheim Animal Health's global headquarters is located in Ingelheim, Germany.
Merial was investigated in connection with a 2007 United Kingdom foot-and-mouth outbreak, after a strain of foot-and-mouth disease alleged to have been sourced from one of their research facilities was found at Pirbright, a farm in Surrey, England, in August 2007. The investigators concluded that "release was most likely due to escape of live virus from the drainage system that connects the vaccine production plant to the sodium hydroxide treatment tanks on another part of the Pirbright site."
The two independent inquiries found that Merial complied with all regulations and committed no breaches of biosecurity.
In 2016, the NOAH Code of Practice Committee found Merial Animal Health to be in breach of 2 out of 4 items under complaint. This related to the promotion of NexGard Spectra® to the veterinary profession by both account managers and technical teams via telephone conversations and webinars from February 2016 onwards.
- "Our History". Boehringer Ingelheim. Retrieved 2020-05-01.
- "Corporate Brochure" (PDF). Boehringer Ingelheim. Retrieved 2020-05-01.
- "Boehringer Ingelheim Closes Deal to Acquire Merial | Bovine Vet Online". www.bovinevetonline.com. Archived from the original on 2017-01-10. Retrieved 2017-01-10.
- "Company | Merial". merial.com. Archived from the original on 2015-11-09. Retrieved 2015-11-03.
- "Sanofi - Key facts & figures". en.sanofi.com. Retrieved 2015-11-03.
- "Sanofi-aventis and Merck to create a Global Leader in Animal Health" (PDF). March 8, 2010. Retrieved November 3, 2015.
- "Initial report on potential breaches to biosecurity at the Pirbright site, 2007". UK Health and Safety Executive. May 12, 2008. Archived from the original on February 1, 2009. Retrieved 2009-04-22.
- National Emergency Epidemiology Group (29 August 2007). "FMD in Surrey, UK, 2007: Epidemiology report on the probable release of FMD virus at the Pirbright site and the transmission of infection to the first infected cattle herd, from investigations up to 29 August 2007 (Day 26)" (PDF). UK Department for Environment, Food and Rural Affairs (DEFRA). Archived from the original (PDF) on 10 April 2009. Retrieved 2009-04-22.
- "Merial Animal Health found in breach of NOAH Code on Promotion". NOAH (National Office of Animal Health). 2016-08-19. Retrieved 2019-12-11.